Piper Sandler Companies has broadened its healthcare investment banking team by appointing Patrick McCormack, M.D. as a managing director. With extensive industry knowledge and clinical expertise McCormack who will be working from the San Francisco office, is a perfect fit not only for the company but also to the fast-evolving world of biopharma market.
Healthcare sector has been facing many challenges including the production of innovative drugs and provision of sufficient funding Mostly in times of crisis. Piper Sandler is among the top investment banking firms and it has been consistently recognized for expertise in this sector. Hiring McCormack is Really another move that shows the company is ready to offer biopharma companies customized advisory services capable of leading to their success in such a fast-changing world.
McCormack comes to Piper Sandler from Wells Fargo Securities, where he was the executive director of the group handling biopharma investment banking. Being a physician and a banker, he has knowledge of both worlds. Many bankers do their job based on the financial side only, but McCormack is well aware of the scientific and clinical aspects that lie behind investments in the healthcare sector. This is his strength in gaining the trust of founders and decision-makers who, apart from developing, are also passionate about treatments.
Mccormack has expressed his delight that he gets to work for a firm which is greatly involved in the healthcare industry as Piper Sandler. He is planning to help biopharma companies in various ways like running mergers and acquisitions, setting up strategic partnerships, and capital-raising transactions, etc. At a time when new therapies like precision medicine, gene therapy, and drug modalities are totally changing our healthcare systems, it is great to have a consultant that understands both worlds science and finance.
In the current market, Piper Sandler’s healthcare investment banking department is considered one of the strongest in the entire industry practically covering the major players of biopharma, life sciences, diagnostics, and healthcare services. With McCormack joining the team, they will be able to engage in lots of equity and M&A transactions. The clients will always have the advantage of working with an associate that is not only thorough in analysis, but also naturally understands the industry, making it easier for the clients to reach their desired level of funding with the eventual aim of completing those major acquisitions.
The hiring of such a high-profile person is typical of the wider changes that are being seen in the investment banking world at the moment. Due to heavy regulatory pressures, which have in many cases limited opportunities, a number of sectors like biotechnology have had to rely on therapeutic areas such as oncology or rare diseases. But, despite all the challenges, these present a tremendous opportunity. Given that firms like Piper Sandler continue to invest in highly qualified people, it is no surprise that McCormack is one of the key additions that the company has recently made.
For the healthcare ecosystem, a move like this is more than just a personnel change. Having competent advisory can be the tipping point that leads to a newly developed drug actually getting to patients instead of hanging in the balance due to lack of funding. Through the increase of its capabilities, Piper Sandler will be in a better position to stimulate deal activity, bolster the creation of novel partnerships, and support the development of new solutions that might benefit millions of patients globally.
